NIH's contrast agent database adds new probes for optical molecular imaging

OCTOBER 27, 2008 -- The Molecular Imaging and Contrast Agent Database (MICAD) has added a number of new probes, including two for optical molecular imaging that target a prostate-specific membrane antigen and lysosomes, respectively. These and 544 other agents for various modalities -- including optical -- are available through MICAD, a key component of the National Institutes of Health (NIH) Roadmap.

OCTOBER 27, 2008 -- The Molecular Imaging and Contrast Agent Database (MICAD) has added a number of new probes, including two for optical molecular imaging: QD-Apt(Dox), which targets a prostate-specific membrane antigen, and IR-2, which targets lysosomes.

These and 544 other agents for various modalities -- including optical -- are available in the MICAD database.

MICAD is a key component of the NIH Roadmap; it is developed by the National Center for Biotechnology Information (NCBI), at the National Institutes of Health (NIH). The mission of the MICAD program is to foster research and development in molecular imaging by providing free accessible online scientific information on in vivo molecular imaging and contrast agents to the community working in the field.

More information:
The Molecular Imaging and Contrast Agent Database (MICAD)
NIH Roadmap

More in Bioimaging